Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic is using its proprietary DIAMOND artificial intelligence (AI) 2.0 platform to discover novel targets for immuno-oncology. The Company maintains offices in Houston, Texas. To learn more, visit and connect with us on Twitter and LinkedIn.SEC declines to impose civil penalties in light of the Company's self-reporting, prompt remediation and cooperation
鑑於公司自我報告、迅速整改和合作，SEC決定不對公司施加民事處罰。
HOUSTON--(BUSINESS WIRE)--Dec. 3, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") today announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (the "SEC"), resolving the previously disclosed SEC investigation arising from the non-disclosure by Kiromic's prior executive management of the clinical holds placed on the investigational new drug ("IND") applications the Company filed with the U.S. Food and Drug Administration (the "FDA") in May 2021. The IND applications pertained to ALEXIS-PRO-1 (Procel) and ALEXIS-ISO-1 (Isocel). In light of the Company's self-reporting, prompt remediation and cooperation, the SEC has determined not to impose a civil penalty on the Company and there are no ongoing undertakings in connection with the settlement.
休斯頓--（業務 wire）--2024年12月3日--kiromic biopharma公司（OTCQB：KRBP）（「kiromic」或「公司」）今天宣佈已與美國證券交易委員會（「SEC」）達成和解協議，解決之前披露的因kiromic的前執行管理層未披露對公司於2021年5月向美國食品藥品監督管理局（「FDA」）提交的臨床新藥（「IND」）申請所施加臨床禁令而引發的SEC調查。IND申請涉及ALEXIS-PRO-1（Procel）和ALEXIS-ISO-1（Isocel）。鑑於公司的自我報告、迅速整改和合作，SEC決定不對公司施加民事罰款，並且與和解相關的任何持續責任也已不再存在。
About Kiromic BioPharma
關於Kiromic生物製藥
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic is using its proprietary DIAMOND artificial intelligence (AI) 2.0 platform to discover novel targets for immuno-oncology. The Company maintains offices in Houston, Texas. To learn more, visit and connect with us on Twitter and LinkedIn.
kiromic biopharma公司是一家臨床階段的全面綜合生物治療公司，正在開發一個多適應症的異基因電芯治療平台，利用伽馬δ細胞的天然效能靶向實體腫瘤。kiromic正在利用其專有的金剛石人工智能（AI）2.0平台發現免疫腫瘤學的新靶點。公司在德克薩斯州休斯頓設有辦事處。要了解更多信息，請訪問並在Twitter和LinkedIn上與我們聯繫。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
聯盟顧問IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
Source: Kiromic BioPharma, Inc.
來源：kiromic biopharma, Inc.
譯文內容由第三人軟體翻譯。
